BREAST CANCER CONNECT powered by COR2ED

COR2ED brings you Independent Medical Education developed by BREAST CANCER CONNECT, experts in Breast Cancer.

[BREAST CANCER CONNECT powered by COR2ED @BreastCaConnect]

🔬 #PrecisionOncology in HER2+ metastatic #breastcancer

❓ What challenges do we face at the pre-analytical phase?
❓ How can we address these challenges to optimise outcomes?

Expert discussion from Prof. Gary Tse, Dr Carlos Barrios, & @OncBrothers

📹 Watch the full video
🎙️ Listen on Spotify/Apple

https://t.co/9A7fEVBQBO

🤝 Endorsed by @BiomarkerCo

Supported by an Independent Educational Grant from Daiichi Sankyo. For HCPs only.

#MedEd #BCSM #PrecisionMedicine

[PRECISION ONCOLOGY CONNECT powered by COR2ED @PresOnc_Connect]

Could better HER2 classification mean more patients accessing targeted treatment options?

Prof. Gary Tse and Dr Carlos Barrios discuss the importance of accurate biomarker testing and reducing missed opportunities in mBC.

#MedEd

[OncoAlert @OncoAlert]

Get expert insights on the latest data in lung, prostate, GI, and breast cancers presented at #ASCO26 . Renowned medical experts join @COR2EDMedEd in Chicago to share their views on data emerging from the meeting. How will new trial data impact clinical practice? Watch the video updates to find out!

https://t.co/TNY8ovSvTr

@herbloong
@ipreeshagul
@PTarantinoMD

[OncoAlert @OncoAlert]

Lung cancer 🫁 update from #ASCO26
👉 https://t.co/Tik3fC02aR

Renowned lung cancer experts join our collaborators at COR2ED at ASCO 2026 to discuss breaking data emerging from the meeting. Watch the video updates for insights on HER2-mutant non-small cell lung cancer (NSCLC) from Drs Herbert Loong and Isabel Preeshagul, and analysis of other key lung cancer trial data from Prof. Mark Socinski.
#LungCancer #NSCLC #SCLC
@herbloong @ipreeshagul

[BREAST CANCER CONNECT powered by COR2ED @BreastCaConnect]

📣#BreastCancer highlights from #ASCO26!

Dr @PtarantinoMD shares his expert insights on key #trialdata from #ASCENT-03, ASCENT-04, #TROPION-Breast02, #SERENA-6, #VIKTORIA-1, & #OPTIMA

How will these data impact clinical practice? Watch his update to find out!

🤝 Programme endorsed by @WarOnCancer

📺See more updates from @ASCO in 𝘏𝘌𝘙2-mutant #NSCLC, #LungCancer, #GIcancer & #ProstateCancer
⬇️
https://t.co/falAIozLmZ

This educational programme is supported by COR2ED

#MedEd #BCSM

[OncoAlert @OncoAlert]

GI and hepatobiliary cancer update from ASCO 2026
Medical oncologist Prof. Hans Prenen joins @COR2EDMedEd in Chicago to share his expert insights on the latest data in colorectal, pancreatic, and liver cancers presented at ASCO 2026. How will late-breaking data impact clinical practice? Watch his video update to find out.

https://t.co/cJdpVtKQUF

[BREAST CANCER CONNECT powered by COR2ED @BreastCaConnect]

HER2 expression can change over time and between tumour sites.

The @OncBrothers and @jhaveri_komal discuss HER2-low and HER2-ultralow classification, including when re-biopsy may help identify patients eligible for HER2-targeted therapies.

#MedEd

[BREAST CANCER CONNECT powered by COR2ED @BreastCaConnect]

Understanding HER2-low and HER2-ultralow classification in metastatic breast cancer

>> A novel therapeutic framework

📹 From @OncBrothers & Dr @jhaveri_komal

Explore key trial data, 2025 CAP reporting template, when/why to perform biopsy, best practice in monitoring AEs & more!

Watch the full video! ⤵️
https://t.co/ShBz8g6WWL

Supported by an Independent Educational Grant from AstraZeneca

#MedEd #BreastCancer #MedTwitter

[OncoAlert @OncoAlert]

Breast Cancer Update from ASCO 2026 : Watch Dr @PTarantinoMD joins @COR2EDMedEd in Chicago to share his views on the latest breast cancer data emerging from ASCO 2026. How will new developments impact clinical practice? Watch his update to find out!

https://t.co/SAFoLcxl4V

[BREAST CANCER CONNECT powered by COR2ED @BreastCaConnect]

📣#BreastCancer highlights from #ASCO26!

Dr @PtarantinoMD shares his expert insights on key #trialdata from #ASCENT-03, ASCENT-04, #TROPION-Breast02, #SERENA-6, #VIKTORIA-1, & #OPTIMA

How will these data impact clinical practice? Watch his update to find out!

🤝 Programme endorsed by @WarOnCancer

📺See more updates from @ASCO in 𝘏𝘌𝘙2-mutant #NSCLC, #LungCancer, #GIcancer & #ProstateCancer
⬇️
https://t.co/falAIozLmZ

This educational programme is supported by COR2ED

#MedEd #BCSM

[OncoAlert @OncoAlert]

Dear Colleagues at #ASCO26
Get expert insights on new #ProstateCancer data emerging from ASCO 2026. Prof. Evan Yu joins @COR2EDMedEd live in Chicago to share his views on how new trial data presented at the meeting could impact the clinical management of patients with prostate cancer. Watch his conference update now.

Watch here👉 https://t.co/OouXnsouqm

[OncoAlert @OncoAlert]

Lung cancer 🫁 update from #ASCO26
👉 https://t.co/TZS21R524b

Renowned lung cancer experts join our collaborators at @COR2EDMedEd at ASCO 2026 to discuss breaking data emerging from the meeting. Watch the video updates for insights on HER2-mutant non-small cell lung cancer (NSCLC) from Drs Herbert Loong and Isabel Preeshagul, and analysis of other key lung cancer trial data from Prof. Mark Socinski.
#LungCancer #NSCLC #SCLC
@herbloong @ipreeshagul

[BREAST CANCER CONNECT powered by COR2ED @BreastCaConnect]

Understanding HER2-low and HER2-ultralow classification in metastatic breast cancer

>> A novel therapeutic framework

📹 From @OncBrothers & Dr @jhaveri_komal

Explore key trial data, 2025 CAP reporting template, when/why to perform biopsy, best practice in monitoring AEs & more!

Watch the full video! ⤵️
https://t.co/ShBz8g6WWL

Supported by an Independent Educational Grant from AstraZeneca

#MedEd #BreastCancer #MedTwitter

[COR2ED @COR2EDMedEd]

📢 #ASCO26 is nearly here, keep a look out for our conference update!

In this video, Dr @ipreeshagul introduces the medical experts who will be joining us at ASCO

➡️Dr @herbloong: 𝘏𝘌𝘙2-mutant NSCLC (along with Dr Preeshagul)

➡️Prof. @MarkSocinski: #NSCLC / #LungCancer

➡️Prof. Evan Yu: #ProstateCancer

➡️Prof. @HPrenen: #GIcancer: #HCC, #LiverCancer, #CRC, #PanCan

➡️ Dr @PTarantinoMD: #BreastCancer

🎬 Keep checking back to see the videos as soon as they’re released: https://t.co/kSgc3cEdxs

𝘏𝘌𝘙2-mutant NSCLC update supported by an Independent Educational Grant from Bayer. All other updates supported by COR2ED

#MedEd #OncTwitter #OncMedEd

[PRECISION ONCOLOGY CONNECT powered by COR2ED @PresOnc_Connect]

➡️ HER2 IHC testing is recommended in p53-aberrant endometrial carcinoma

➡️ It may be considered in selected advanced/recurrent cervical & ovarian cancers when evaluating eligibility for HER2-targeted therapies

🧬 Find out more about #HER2 testing in gynecological cancers, best practice, & treatment selection

📺 From Prof. Fernando Soares

Get the slides for more: https://t.co/aeqP7LQjSE

Supported by an Independent Educational Grant from Daiichi Sankyo. For HCPs only.

#MedEd #obgyn #MedTwitter #precisionmedicine

[BREAST CANCER CONNECT powered by COR2ED @BreastCaConnect]

Could better HER2 classification mean more patients accessing targeted treatment options?

Prof. Gary Tse and Dr Carlos Barrios discuss the importance of accurate biomarker testing and reducing missed opportunities in mBC.

#MedEd

[PRECISION ONCOLOGY CONNECT powered by COR2ED @PresOnc_Connect]

Pre-analytical phase challenges & biomarker testing in HER2+ metastatic breast cancer

From Prof. Gary Tse, Dr Carlos Barrios, & @OncBrothers

Highlights in this video 📹

Watch full video or listen on Spotify/Apple: https://t.co/lTHd09bmyY

>> Endorsed by @BiomarkerCo

Supported by an Independent Educational Grant from Daiichi Sankyo. For HCPs only.

#MedEd #BCSM #PrecisionMedicine

[BREAST CANCER CONNECT powered by COR2ED @BreastCaConnect]

📣#MedEd resources: Metastatic #breastcancer 📣

Understanding HER2-low and HER2-ultralow classification in metastatic breast cancer

>> A novel therapeutic framework

From @OncBrothers & Dr @jhaveri_komal

📹 Watch the full video or listen on Spotify or Apple: https://t.co/ShBz8g6p7d

Supported by an Independent Educational Grant from AstraZeneca

#MedEd #BCSM #MedTwitter #OncTwtter

[BREAST CANCER CONNECT powered by COR2ED @BreastCaConnect]

Pre-analytical phase challenges & biomarker testing in HER2+ metastatic breast cancer

From Prof. Gary Tse, Dr Carlos Barrios, &
@OncBrothers

Highlights in this video 📹

>> Endorsed by @agingbiomarkers

Supported by an Independent Educational Grant from Daiichi Sankyo. For HCPs only.

[BREAST CANCER CONNECT powered by COR2ED @BreastCaConnect]

ADCs in HER2+ metastatic breast cancer: management of adverse events

Move beyond describing T-DXd toxicities as “manageable”

Get clear, practical strategies for managing treatment-related adverse events

➡️ Nausea + vomiting
➡️ Fatigue
➡️ ILD

From an expert panel: Dr @stolaney1, Prof. @Shaheenah1, Prof. @JavierCortesMD, @CarlaWhitbread, Dr Grazyna Suchodolska, & Prof. Giuseppe Curigliano

Download the BluePrint & watch the expert videos 📺 for further insights: https://t.co/gdtVCj6r1w

🤝 Endorsed by the European Oncology Nursing Society (@cancernurseEU) and @EuropaDonnaEUR

Supported by an Independent Educational Grant from AstraZeneca

#MedEd #MedTwitter #BCSM

[BREAST CANCER CONNECT powered by COR2ED @BreastCaConnect]

The evolving understanding of HER2 expression has transformed the management of metastatic breast cancer 💮

Data shows that T-DXd provides clinically meaningful benefit in pts with HER2-low/HER2-ultralow disease

HER2 assessment has shifted from a binary classification to a therapeutic continuum

Explore the implications for clinical practice with educational resources from @OncBrothers & @jhaveri_komal

📹 Watch the full video or listen to the podcast on Spotify or Apple: https://t.co/ShBz8g6p7d

Supported by an Independent Educational Grant from AstraZeneca

#MedEd #breastcancer #MedTwitter #BCSM

[BREAST CANCER CONNECT powered by COR2ED @BreastCaConnect]

ADCs in HER2+ metastatic breast cancer: management of adverse events

Get step-by-step strategies to support effective management of T-DXd–related adverse events in HER2+ mBC

✔️ N/V
✔️ Fatigue
✔️ Interstitial lung disease (rare but critical)

Downloadable BluePrint for HCPs & patients

From Dr @stolaney1, Prof. @Shaheenah1, Prof. @JavierCortesMD, @CarlaWhitbread, Dr Grazyna Suchodolska, & Prof. Giuseppe Curigliano

https://t.co/gdtVCj6r1w

🤝 Endorsed by the European Oncology Nursing Society (@cancernurseEU) and @EuropaDonnaEUR

Supported by an Independent Educational Grant from AstraZeneca

#MedEd #MedTwitter #BCSM 📺